PI3Kδ inhibitors for the treatment of cancer: a patent review (2015-present)

References

• Norman P. Selective PI3Kd inhibitors, a review of the patent literature. Expert Opin Ther Pat. 2011;21:1773–1790.
   PubMed Web of Science ®Google Scholar
• Garces AE, Stocks MJ. Class 1 PI3K clinical candidates and recent inhibitor design strategies: a medicinal chemistry perspective. J Med Chem. 2019;62:4815–4850.
   PubMed Web of Science ®Google Scholar
• Bui M, Hao X, Shin Y, et al. Synthesis and SAR study of potent and selective PI3Kd inhibitors. Bioorg Med Chem Lett. 2015;25:1104–1109.
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res. 1999;253:239–254.
   PubMed Web of Science ®Google Scholar
• Lucas CL, Chandra A, Nejentsev S, et al. PI3Kd and primary immunodeficiencies. Nat Rev Immunol. 2016;16:702–714.
   Google Scholar
• Michalovich D, Nejentsev S. Activated PI3 kinase delta syndrome: from genetics to therapy. Front Immunol. 2018;9:369.
   Google Scholar
• Jia H, Dai G, Su W, et al. Discovery, optimization, and evaluation of potent and highly selective PI3Kgamma-PI3Kd dual inhibitors. J Med Chem. 2019;62:4936–4948.
   Google Scholar
• Vogt PK, Hart JR, Gymnopoulos M. Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol. 2010;347:79–104.
   Google Scholar
• Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene. 2008;27:5486–5496.
   PubMed Web of Science ®Google Scholar
• Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008;27:5497–5510.
   PubMed Web of Science ®Google Scholar
• Wei M, Wang X, Song Z, et al. Targeting PI3Kd: emerging therapy for chronic lymphocytic leukemia and beyond. Med Res Rev. 2015;35:720–752.
   PubMed Web of Science ®Google Scholar
• Katso R, Okkenhaug K, Ahmadi K, et al. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2001;17:615–675.
   PubMed Web of Science ®Google Scholar
• Zirlik K, Veelken H. Idelalisib. Recent Results Cancer Res. 2018;212:243–264.
   PubMedGoogle Scholar
• Yang Q, Modi P, Newcomb T, et al. Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. Clin Cancer Res. 2015;21:1537–1542.
   PubMed Web of Science ®Google Scholar
• Shah A, Mangaonkar A. Idelalisib: a novel PI3Kd inhibitor for chronic lymphocytic leukemia. Ann Pharmacother. 2015;49:1162–1170.
   PubMed Web of Science ®Google Scholar
• Vangapandu HV, Jain N, Gandhi V. Duvelisib: a phosphoinositide-3 kinase d/? inhibitor for chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2017;26:625–632.
   PubMed Web of Science ®Google Scholar
• Flinn IW, O’Brien S, Kahl B, et al. Duvelisib, a novel oral dual inhibitor of PI3K-d?, is clinically active in advanced hematologic malignancies. Blood. 2018;131:877–887.
   PubMed Web of Science ®Google Scholar
• Nastoupil LJ, Lunning MA, Vose JM, et al. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol. 2019;6:e100–9.
   PubMed Web of Science ®Google Scholar
• Burris HA, Flinn IW, Patel MR, et al. Umbralisib, a novel PI3Kd and casein kinase-1e inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018;19:486–496.
   PubMed Web of Science ®Google Scholar
• Cushing TD, Hao X, Shin Y, et al. Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kd inhibitors for inflammation and autoimmune disease. J Med Chem. 2015;58:480–511.
   PubMed Web of Science ®Google Scholar
• Perry MWD, Abdulai R, Mogemark M, et al. Evolution of PI3K? and d inhibitors for inflammatory and autoimmune diseases. J Med Chem. 2019;62:4783–4814.
   PubMed Web of Science ®Google Scholar
• Patel K, Pagel JM. Exploring a future for PI3K inhibitors in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2019;14:292–301.
   PubMed Web of Science ®Google Scholar
• Moreno O, Butler T, Zann V, et al. Safety, Pharmacokinetics, and pharmacodynamics of ME-401, an oral, potent, and selective inhibitor of phosphatidylinositol 3-kinase P110d, following single ascending dose administration to healthy volunteers. Clin Ther. 2018;40:1855–1867.
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Ramchandren R, Yacoub A, et al. Parsaclisib, a potent and highly selective PI3Kd inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019;133:1742–1752.
   PubMed Web of Science ®Google Scholar
• Phillips TJ, Forero-Torres A, Sher T, et al. Phase 1 study of the PI3Kd inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. Blood. 2018;132:293–306.
   PubMed Web of Science ®Google Scholar
• Shin N, Li YL, Mei S, et al. INCB040093 is a novel PI3Kd inhibitor for the treatment of B cell lymphoid malignancies. J Pharmacol Exp Ther. 2018;364:120–130.
   PubMed Web of Science ®Google Scholar
• Patel L, Chandrasekhar J, Evarts J, et al. Discovery of orally efficacious phosphoinositide 3-kinase d inhibitors with improved metabolic stability. J Med Chem. 2016;59:9228–9242.
   PubMed Web of Science ®Google Scholar
• Shugg RP, Thomson A, Tanabe N, et al. Effects of isoform-selective phosphatidylinositol 3-kinase inhibitors on osteoclasts: actions on cytoskeletal organization, survival, and resorption. J Biol Chem. 2013;288:35346–35357.
   PubMed Web of Science ®Google Scholar
• Ino H, Wilson R, Terao T, et al. Evaluation of the safety, tolerability, and pharmacokinetics of GSK2269557 (Nemiralisib) administered via dry powder inhaler to healthy japanese subjects. Clin Pharmacol Drug Dev. 2019;8:78–86.
   PubMed Web of Science ®Google Scholar
• Down K, Amour A, Baldwin IR, et al. Optimization of novel indazoles as highly potent and selective inhibitors of phosphoinositide 3-kinase d for the treatment of respiratory disease. J Med Chem. 2015;58:7381–7399.
   PubMed Web of Science ®Google Scholar
• Pearson D, Garnier M, Luneau A, et al. 19F-NMR-based determination of the absorption, metabolism and excretion of the oral phosphatidylinositol-3-kinase (PI3K) delta inhibitor leniolisib (CDZ173) in healthy volunteers. Xenobiotica. 2019;49:953–960.
   PubMed Web of Science ®Google Scholar
• Allen RA, Brookings DC, Powell MJ, et al. Seletalisib: characterization of a novel, potent, and selective inhibitor of PI3Kd. J Pharmacol Exp Ther. 2017;361:429–440.
   PubMed Web of Science ®Google Scholar
• Locatelli SL, Careddu G, Serio S, et al. Targeting cancer cells and tumor microenvironment in preclinical and clinical models of hodgkin lymphoma using the dual PI3Kd/? inhibitor RP6530. Clin Cancer Res. 2019;25:1098–1112.
   PubMed Web of Science ®Google Scholar
• Ito Y, Makita S. Tobinai K1. Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019;19:197–209.
   PubMed Web of Science ®Google Scholar
• Hogg C. Chi-Med initiates first-in-human clinical trial of novel PI3K inhibitor HMPL-689. Hutchicon China Meditech Limited. 2016.
   Google Scholar
• Feng YF, Duan WM, Fan S, et al. Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6- pyridylquinazolines as potent PI3Kd inhibitors. Bioorg Med Chem. 2019; 27(19):115035.
   Google Scholar
• Erdmann T, Klener P, Lynch JT, et al. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood. 2017;130:310–322.
   PubMed Web of Science ®Google Scholar
• Calitor Sciences Llc, Sunshine Lake Rharma Co Ltd. Substituted aminopyrimidine compounds and methods of use. WO2015042078. 2015.
   Google Scholar
• Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof. WO2015061204. 2015.
   Google Scholar
• Sunshine Lake Pharma Co Ltd, Calitor Sciences Llc. Substituted aminopyrimidine compounds and methods of use. WO2016149160. 2016.
   Google Scholar
• Sunshine Lake Pharma Co Ltd, Calitor Sciences Llc. Substituted aminopyrimidine compounds and methods of use. WO2016134668. 2016.
   Google Scholar
• Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof. WO2015051241. 2015.
   Google Scholar
• Rhizen Pharmaceuticals Sa. Pi3k protein kinase inhibitors, particularly delta and/or gamma inhibitors. WO2015001491. 2015.
   Google Scholar
• Gilead Sciences Inc. Phosphatidylinositol 3-kinase inhibitors. WO2015200352. 2015.
   Google Scholar
• Neuform Pharmaceuticals Inc. Deuterated compounds for treating hematologic malignant, inflammatory and autoimmune diseases. WO2017087207. 2017.
   Google Scholar
• Trustees Of Columbia Univeristy. Compounds, compositionals, and methods for treating T-cell acute lymphoblastic leukemia. WO2019028375. 2019.
   Google Scholar
• Fronthera U S Pharmaceuticals Llc. Pi3 kinase inhibitors and uses thereof. WO2019028395. 2019.
   Google Scholar
• Korea Res Inst Chemical Tech. Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient. WO2016204429. 2016.
   Google Scholar
• Bioway Inc. Novel quinazolinone derivatives inhibiting pi3k and pharmaceutical composition containing same. WO2018012907. 2018.
   Google Scholar
• Yuhan Corp. Quinazoline derivative or its salt and pharmaceutical composition comprising the same. WO2017188720. 2017.
   Google Scholar
• Empire Technology Dev Llc. Methods and compositions for treating and preventing dag formation. WO2017087234. 2017.
   Google Scholar
• Novartis A. Substituted quinazolin-4-one derivatives. WO2015010641. 2015.
   Google Scholar
• Gilead Sciences Inc. Phosphatidylinositol 3-kinase inhibitors. WO2015191752. 2015.
   Google Scholar
• Gilead Sciences Inc. Phosphatidylinositol 3-kinase inhibitors. WO2015191745. 2015.
   Google Scholar
• Gilead Sciences Inc. Phosphatidylinositol 3-kinase inhibitors. WO2015191726. 2015.
   Google Scholar
• Concert Pharmaceuticals Inc. Deuterated phenylquinazolinone and phenylisoquinolinone compounds. WO2015179772. 2015.
   Google Scholar
• Suzhou Zelgen Biopharmaceuticals Co Ltd. Deuterated quinazolinone compound and pharmaceutical composition comprising same. WO2015113521. 2015.
   Google Scholar
• Neuform Pharmaceuticals Inc. Deuterated compounds for treating blood cancers, and compositions and methods thereof. WO2017079003. 2017.
   Google Scholar
• Lupin Ltd. Quinolizinone derivatives as pi3k inhibitors. WO2016001855. 2016.
   Google Scholar
• Nanjing Sanhome Pharmaceutical Co Ltd. Substituted pyrimidine compounds as phosphatidylinositol 3-kinase ? inhibitor and use thereof. WO2016141855. 2016.
   Google Scholar
• Zhejiang University. Benzothiazine and benzothiadiazine compounds and preparation and use. WO2017133655. 2017.
   Google Scholar
• Zhejiang Vimgreen Pharma Ltd. Quinoline analogs as phosphatidylinositol 3-kinase inhibitors. WO2017155741. 2017.
   Google Scholar
• Chiesi Farm Spa. Chromene derivatives as phoshoinositide 3-kinases inhibitors. WO2016166239. 2016.
   Google Scholar
• Chiesi Farma Spa. Isochromene derivatives as phoshoinositide 3-kinases inhibitors. WO2015091685. 2015.
   Google Scholar
• Beigene Ltd. Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors. WO2018103688. 2018.
   Google Scholar
• Beigene Ltd. Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors. WO2019047915. 2019.
   Google Scholar
• Squibb Bristol Myers Co. Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors. WO2016064958. 2016.
   Google Scholar
• Squibb Bristol Myers Co. Bicyclic heteroaryl amine compounds as pi3k inhibitors. WO2016064957. 2016.
   Google Scholar
• Chiesi Farm Spa. Pyrazole derivatives as phosphoinositide 3-kinases inhibitors. WO2017134053. 2017.
   Google Scholar
• Medivation Technologies Inc. Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors O brutons kinase (btk). WO2015069441. 2015.
   Google Scholar
• Outotec Finland Oy. Process for operating a sulfuric acid plant. WO2015058804. 2015.
   Google Scholar
• Ye BH. Pyrazolopyrimidine compound as pi3k inhibitor and use thereof. WO2018082444. 2018.
   Google Scholar
• Qianwan Pharmaceutical Tech (shenzhen) Co Ltd. Imidazopyridine compound and uses in preparation of pi3k inhibitor. WO2017049498. 2017.
   Google Scholar
• Hutchison Medipharma Ltd. Novel heteroaryl and heterocycle compounds, compositions and methods. WO2016119707. 2016.
   Google Scholar
• Shanghai Fochon Pharmaceutical Co Ltd. Certain protein kinase inhibitors. WO2016066142. 2016.
   Google Scholar
• Hutchison Medipharma Ltd. Novel imidazopyridazine compounds and their use. WO2016045591. 2016.
   Google Scholar
• Takeda Pharmaceutical. Azaindole derivatives. WO2015106014. 2015.
   Google Scholar
• Takeda Pharmaceutical. Azaindole derivatives. WO2015106012. 2015.
   Google Scholar
• Glaxosmithkline Ip Dev Ltd. Chemical compounds. WO2018029126. 2018.
   Google Scholar
• Glaxosmithkline Ip Dev Ltd. Oxepinopyrazole derivatives as inhibitors of pi3-kinase activity. WO2018192864. 2018.
   Google Scholar
• Daiichi Sankyo Co Ltd. 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors. WO2016157074. 2016.
   Google Scholar
• Shanghai Yingli Pharmaceutical Co Ltd. Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof. WO2015043398. 2015.
   Google Scholar
• Shanghai Yingli Pharmaceutical Co Ltd. Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof. WO2015055071. 2015.
   Google Scholar
• Celon Pharma S A. 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer. WO2016157091. 2016.
   Google Scholar
• Nanjing Gator Meditech Company Ltd, Jilin University. Pyrimidine derivative, cytotoxic agent, pharmaceutical composition and use thereof. WO2016127455. 2016.
   Google Scholar
• Merck Sharp & Dohme. Purine inhibitors of human phosphatidylinositol 3-kinase delta. WO2017166104. 2017.
   Google Scholar
• Merck Sharp & Dohme. Purine inhibitors of human phosphatidylinositol 3-kinase delta. WO2017000125. 2017.
   Google Scholar
• Merck Sharp & Dohme. Purine inhibitors of human phosphatidylinositol 3-kinase delta. WO2016004807. 2016.
   Google Scholar
• Merck Sharp & Dohme. Purine inhibitors of human phosphatidylinositol 3-kinase delta. WO2015188369. 2015.
   Google Scholar
• Xin M, Zhang SQ, Zhang H, et al. Preparation of 6-arylquinoline compounds as PI3Kd inhibitors for treating inflammation and tumor. CN105237484. 2016.
   Google Scholar
• Xin M, Duan W, Feng Y, et al. Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kd) inhibitors. J Enzyme Inhib Med Chem. 2018;33:651–656.
   PubMed Web of Science ®Google Scholar
• Xin M, Duan W, Feng Y, et al. Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kd) inhibitors. Bioorg Med Chem. 2018;26:2028–2040.
   PubMed Web of Science ®Google Scholar
• Hei YY, Zhang SQ, Feng Y, et al. Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors. Bioorg Med Chem. 2019;27(20):114930.
   PubMed Web of Science ®Google Scholar
• Xin M, Hei YY, Zhang H, et al. Design and synthesis of novel 6-aryl substituted 4-anilinequinazoline derivatives as potential PI3Kd inhibitors. Bioorg Med Chem Lett. 2017;27:1972–1977.
   PubMed Web of Science ®Google Scholar
• Feng Y, Duan W, Fan S, et al. Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6-pyridylquinazolines as potent PI3Kd inhibitors. Bioorg Med Chem. 2019;27:115035.
   Google Scholar
• Hefei Inst Physical Sci Cas, Hefei Cosource Pharmaceutical Co Ltd. New pi3k kinase inhibitor. WO2016101553. 2016.
   Google Scholar
• Incyte Corp. Heterocyclic compounds as pi3k-gamma inhibitors. WO2017223414. 2017.
   Google Scholar
• Dana-farber Cancer Inst Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating pi3k-mediated disorders. WO2017177092. 2017.
   Google Scholar
• Glaxosmithkline Ip Dev Ltd. Chemical compounds as inhibitors of kinase activity. WO2017137535. 2017.
   Google Scholar
• Astrazeneca Ab. 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1H-isoindol-1-one derivatives and their use as dual inhibitors of phosphatidylinositol 3-kinase delta & gamma. WO2018055040. 2018.
   Google Scholar
• Merck Sharp & Dohme. Purine inhibitors of human phosphatidylinositol 3-kinase delta. WO2019125839. 2019.
   Google Scholar
• Merck Sharp & Dohme. Purine inhibitors of human phosphatidylinositol 3-kinase delta. WO2019119207. 2019.
   Google Scholar
• Merck Sharp & Dohme. Purine inhibitors of human phosphatidylinositol 3-kinase delta. WO2019125838. 2019.
   Google Scholar
• Merck Sharp & Dohme. Purine inhibitors of human phosphatidylinositol 3-kinase delta. WO2019119206. 2019.
   Google Scholar
• Preite S, Gomez-Rodriguez J, Cannons JL, et al. T and B-cell signaling in activated PI3K delta syndrome: from immunodeficiency to autoimmunity. Immunol Rev. 2019;291:154–173.
   PubMed Web of Science ®Google Scholar
• Frustaci AM, Tedeschi A, Deodato M, et al. Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2019;15:2227–2239.
   Google Scholar
• Katsuya H, Cook LBM, Rowan AG, et al. Phosphatidylinositol 3-kinase-d (PI3K-d) is a potential therapeutic target in adult T-cell leukemia-lymphoma. Biomark Res. 2018;6:24.
   PubMed Web of Science ®Google Scholar
• Hoegenauer K, Soldermann N, Hebach C, et al. Discovery of novel pyrrolidineoxy-substituted heteroaromatics as potent and selective PI3K delta inhibitors with improved physicochemical properties. Bioorg Med Chem Lett. 2016;26:5657–5662.
   PubMed Web of Science ®Google Scholar
• Dalton SE, Dittus L, Thomas DA, et al. Selectively targeting the kinome-conserved lysine of PI3Kd as a general approach to covalent kinase inhibition. J Am Chem Soc. 2018;140:932–939.
   PubMed Web of Science ®Google Scholar
• Hawkins PT, Stephens LR. PI3K signalling in inflammation. Biochim Biophys Acta. 2015;1851:882–897.
   PubMed Web of Science ®Google Scholar